IDD 1
Alternative Names: Dendritic cell/recombinant prostate-specific antigen vaccine; Dendritophages®/rPSA vaccine; Eladem; Eladem-1™; Eladem-2; IDD-1; Prostate cancer vaccine - IDM PharmaLatest Information Update: 20 Oct 2008
At a glance
- Originator IDM Pharma
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 23 Aug 2005 Phase-II clinical trials in Prostate cancer in Europe (Parenteral)
- 16 Aug 2005 IDM S.A. has merged with Epimmune to form IDM Pharma
- 07 Apr 2005 Clinical development is ongoing